Prophylaxis in haemophilia should be life-long.
作者信息
Makris Mike
机构信息
Department of Cardiovascular Science, University of Sheffield, Royal Hallamshire Hospital, Sheffield, UK.
出版信息
Blood Transfus. 2012 Apr;10(2):165-8. doi: 10.2450/2012.0147-11. Epub 2012 Feb 13.
Abstract
摘要
相似文献
1
Prophylaxis in haemophilia should be life-long.血友病的预防应该是终身的。
Blood Transfus. 2012 Apr;10(2):165-8. doi: 10.2450/2012.0147-11. Epub 2012 Feb 13.
2
Prophylaxis for adults with haemophilia: one size does not fit all.成人血友病的预防：一种方法并不适用于所有人。
Blood Transfus. 2012 Apr;10(2):169-73. doi: 10.2450/2012.0174-11.
3
Maintenance of treatment logs by haemophilia patients.血友病患者治疗日志的记录
Haemophilia. 2010 May;16(3):545-7. doi: 10.1111/j.1365-2516.2009.02169.x. Epub 2009 Dec 29.
4
Choice of factor VIII/IX regimen in adolescents and young adults with severe or moderately severe haemophilia. A French national observational study (ORTHem 15-25).重度或中度重度血友病青少年及年轻成人的凝血因子 VIII/IX 治疗方案选择。一项法国全国性观察性研究（ORTHem 15 - 25）
Thromb Res. 2017 Mar;151:17-22. doi: 10.1016/j.thromres.2016.12.023. Epub 2016 Dec 28.
5
Guidelines on the use of prophylactic factor replacement for children and adults with Haemophilia A and B.甲型和乙型血友病儿童及成人预防性因子替代治疗使用指南。
Br J Haematol. 2020 Sep;190(5):684-695. doi: 10.1111/bjh.16704. Epub 2020 May 10.
6
Sodium content in products used to treat haemophilia.用于治疗血友病的产品中的钠含量。
Haemophilia. 2016 Jul;22(4):e324-7. doi: 10.1111/hae.12948. Epub 2016 May 26.
7
A comparison of the treatment of patients with factor IX deficiency to that of those with factor VIII deficiency: results of an International Survey conducted as part of the International FIX Treatment Network.IX因子缺乏症患者与VIII因子缺乏症患者治疗情况的比较：作为国际IX因子治疗网络一部分开展的一项国际调查结果
Haemophilia. 2014 Sep;20(5):e362-4. doi: 10.1111/hae.12487. Epub 2014 Aug 25.
8
The use of enhanced half-life coagulation factor concentrates in routine clinical practice: guidance from UKHCDO.在常规临床实践中使用延长半衰期的凝血因子浓缩物：英国血液学标准委员会的指南
Haemophilia. 2016 Jul;22(4):487-98. doi: 10.1111/hae.13013. Epub 2016 Jun 16.
9
[Clinical effects of FEIBA on hemophilia patients with inhibitors to factor VIII or IX].[活化凝血酶原复合物（FEIBA）对伴有Ⅷ或Ⅸ因子抑制物的血友病患者的临床疗效]
Nihon Ketsueki Gakkai Zasshi. 1982 Sep;45(5):987-92.
10
Cataract surgery in haemophilia.
Haemophilia. 2013 Nov;19(6):e371-2. doi: 10.1111/hae.12212. Epub 2013 Jun 17.
引用本文的文献
1
Quality-of-Life Assessment and Pharmacokinetic Study in Hemophilia A Patients Undergoing Prophylactic Treatment.接受预防性治疗的甲型血友病患者的生活质量评估及药代动力学研究
Pharmacy (Basel). 2025 Feb 2;13(1):16. doi: 10.3390/pharmacy13010016.
2
A Retrospective Observational Study of Quality of Life in a Northern Greece Population of People with Haemophilia.希腊北部血友病患者人群生活质量的回顾性观察研究
Life (Basel). 2024 May 29;14(6):697. doi: 10.3390/life14060697.
3
Delivery of DNA-Based Therapeutics for Treatment of Chronic Diseases.用于治疗慢性病的基于DNA的疗法的递送
Pharmaceutics. 2024 Apr 13;16(4):535. doi: 10.3390/pharmaceutics16040535.
4
genome editing using 244- LNPs and low-dose AAV achieves therapeutic threshold in hemophilia A mice.使用244-LNPs和低剂量腺相关病毒进行基因组编辑可在A型血友病小鼠中达到治疗阈值。
Mol Ther Nucleic Acids. 2023 Oct 7;34:102050. doi: 10.1016/j.omtn.2023.102050. eCollection 2023 Dec 12.
5
Medication Adherence for Haemophilia Patients: Outcome of Prophylaxis Treatment Intervention.血友病患者的药物依从性：预防性治疗干预的结果
Healthcare (Basel). 2021 Dec 8;9(12):1702. doi: 10.3390/healthcare9121702.
6
Outcome of Surgical Management of Hemophilic Pseudotumor: Review of 10 Cases from Single-Center.血友病性假瘤手术治疗的结果：单中心 10 例回顾性研究。
Orthop Surg. 2022 Jan;14(1):27-34. doi: 10.1111/os.13174. Epub 2021 Nov 28.
7
Indirect Treatment Comparison of Damoctocog Alfa Pegol versus Turoctocog Alfa Pegol as Prophylactic Treatment in Patients with Hemophilia A.达莫凝血因子α聚乙二醇与图罗凝血因子α聚乙二醇作为A型血友病患者预防性治疗的间接治疗比较
J Blood Med. 2021 Nov 1;12:935-943. doi: 10.2147/JBM.S321288. eCollection 2021.
8
Rare but not Abdicated: Status of Haemophilia in foothills of Himalaya, Uttarakhand: A cross-sectional study.罕见但并非被忽视：北阿坎德邦喜马拉雅山麓地区血友病的现状：一项横断面研究
J Family Med Prim Care. 2021 Mar;10(3):1437-1442. doi: 10.4103/jfmpc.jfmpc_1613_20. Epub 2021 Apr 8.
9
Adherence to prophylaxis in adolescents and young adults with severe haemophilia: a qualitative study with healthcare professionals.青少年和年轻成人重度血友病患者预防治疗的依从性：一项与医疗保健专业人员开展的定性研究
Health Psychol Behav Med. 2020 Jan 28;8(1):55-72. doi: 10.1080/21642850.2020.1718501.
10
Adherence to prophylaxis in adolescents and young adults with severe haemophilia A, a qualitative study with patients.对重度甲型血友病青少年和青年患者预防治疗依从性的定性研究
Health Psychol Behav Med. 2018 Sep 24;6(1):277-300. doi: 10.1080/21642850.2018.1493384.
本文引用的文献
1
Early prophylaxis/FVIII tolerization regimen that avoids immunological danger signals is still effective in minimizing FVIII inhibitor developments in previously untreated patients--long-term follow-up and continuing experience.避免免疫危险信号的早期预防/因子VIII耐受方案在使既往未治疗患者的因子VIII抑制剂形成最小化方面仍然有效——长期随访及持续经验。
Haemophilia. 2012 Jan;18(1):e18-20. doi: 10.1111/j.1365-2516.2011.02659.x. Epub 2011 Sep 27.
2
Clotting factor concentrates given to prevent bleeding and bleeding-related complications in people with hemophilia A or B.凝血因子浓缩物用于预防甲型或乙型血友病患者的出血及与出血相关的并发症。
Cochrane Database Syst Rev. 2011 Sep 7(9):CD003429. doi: 10.1002/14651858.CD003429.pub4.
3
A survey of the outcome of prophylaxis, on-demand or combined treatment in 20-35 year old men with severe haemophilia in four European countries.对四个欧洲国家20至35岁重度血友病男性进行预防治疗、按需治疗或联合治疗的结果调查。
Haemophilia. 2011 Sep;17(5):e842-3. doi: 10.1111/j.1365-2516.2011.02582.x. Epub 2011 Jun 7.
4
A randomized clinical trial of prophylaxis in children with hemophilia A (the ESPRIT Study).一项针对血友病 A 患儿的预防治疗的随机临床试验（ESPRIT 研究）。
J Thromb Haemost. 2011 Apr;9(4):700-10. doi: 10.1111/j.1538-7836.2011.04214.x.
5
Hemophilia: new protein therapeutics.血友病：新型蛋白质治疗药物。
Hematology Am Soc Hematol Educ Program. 2010;2010:203-9. doi: 10.1182/asheducation-2010.1.203.
6
Associations between intracranial haemorrhage and prescribed prophylaxis in a large cohort of haemophilia patients in the United States.在美国一个大型血友病患者队列中，颅内出血与预防性治疗的相关性。
Br J Haematol. 2011 Jan;152(2):211-6. doi: 10.1111/j.1365-2141.2010.08469.x. Epub 2010 Nov 29.
7
Implications of coagulation factor VIII and IX pharmacokinetics in the prophylactic treatment of haemophilia.VIII 和 IX 凝血因子药代动力学在血友病预防治疗中的意义。
Haemophilia. 2011 Jan;17(1):2-10. doi: 10.1111/j.1365-2516.2010.02370.x. Epub 2010 Aug 22.
8
Prophylaxis in the haemophilia population.血友病人群的预防。
Haemophilia. 2010 Jul;16 Suppl 5:181-8. doi: 10.1111/j.1365-2516.2010.02318.x.
9
Awaiting evidence-based recommendations on prophylaxis in adult patients.等待关于成年患者预防措施的循证推荐意见。
Haemophilia. 2010 Nov;16(6):955-6. doi: 10.1111/j.1365-2516.2010.02340.x.
10
New early prophylaxis regimen that avoids immunological danger signals can reduce FVIII inhibitor development.新的早期预防方案避免了免疫危险信号，可降低 FVIII 抑制剂的产生。
Haemophilia. 2010 Mar;16(2):256-62. doi: 10.1111/j.1365-2516.2009.02122.x. Epub 2009 Oct 29.
Zotero 插件